PD-L1, Programmed death-ligand 1, also known as B7-H1 and CD274, is a cell surface glycoprotein and a member of the B7 family of co-stimulatory molecules. CD274 is expressed constitutively on macrophages and dendritic cells, and is induced on activated T-cells, B-cells, endothelial cells and epithelial cells in response to interferons. PD-L1 has dual function: inhibition of activated effector T cells and co-stimulation of naïve T cells. PD-L1 has also been shown to be upregulated in cancer cells in order to invade the host immune system. Anti-PD-L1-SAP could be used as an effective tool to study cancer and the immune system.
Anti-PD-L1-SAP eliminates cells expressing human PD-L1 (CD274, B7-H1).
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.